Rate Of Conversion From Unresectable To Resectable Metastatic Colorectal Cancer (Mcrc) In Real-World Patients (Rwp) Treated With Folfixiri +/- Bevacizumab: A Population-Based Retrospective Cohort Study.

Tayyaba Bhatti,Michael Moser, Jon Tan,Adnan Zaidi,Duc Le,Haji I. Chalchal,John Shaw,Selliah Kanthan,Mussawar Iqbal,Yigang Luo,Kamal Haider, Tehmina Asif,Dueck Dorie-Anna,Dilip Gill,Nathan Ginther,Shahid Ahmed

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览6

暂无评分

摘要

21Background: Recent evidence from randomized trials suggests that FOLFOXIRI (5FU, oxaliplatin, and irinotecan) ± bevacizumab is associated with higher response rates with a potential for conversio...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要